Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy
Meixi Hao(China Pharmaceutical University), Siyuan Hou(China Pharmaceutical University), Weishuo Li(China Pharmaceutical University), Kaiming Li(China Pharmaceutical University), Lingjing Xue(China Pharmaceutical University), Qifan Hu(China Pharmaceutical University), Lulu Zhu(China Pharmaceutical University), Yue Chen(China Pharmaceutical University), Hongbin Sun(China Pharmaceutical University), Caoyun Ju(China Pharmaceutical University), Can Zhang(China Pharmaceutical University)
Cited by 172
Abstract
T cells or human chimeric antigen receptor T cells, resulted in superior antitumor efficacy in mouse models of melanoma and glioblastoma. Glioblastoma was completely eradicated in three of the five mice receiving surface anchor-engineered chimeric antigen receptor T cells, whereas mice in other treatment groups survived no more than 64 days. Moreover, the administration of engineered T cells showed no obvious systemic side effects. These cell-surface anchor-engineered T cells hold translational potential because of their simple generation and their safety profile.
Related Papers
No related papers found
Powered by citation graph analysis